2025-08-19 - Analysis Report
Okay, here's an analysis of Merck & Co Inc (MRK) based on the provided data, formatted as requested.

## Merck & Co Inc (MRK) Analysis

Merck & Co Inc is a global pharmaceutical company that develops and markets a wide range of medicines, vaccines, and animal health products.

### 1. Performance vs. S&P 500 (VOO)

*   **MRK Cumulative Return:** -8.02%
*   **VOO Cumulative Return:** 100.85%
*   **Absolute Divergence:** -95.0 (MRK is significantly underperforming the S&P 500)
*   **Relative Divergence:** 0.1 (This suggests the current divergence is near the lowest end of its historical range)

**Analysis:** MRK has significantly underperformed the S&P 500, with a substantial negative divergence. The relative divergence suggests this underperformance is near a historical low, potentially indicating a future rebound.  However, the absolute difference is so large, a significant change in the company's fundamentals or market sentiment would be needed to close the gap.

**Alpha, Beta Analysis:**

| Year       | CAGR   | MDD    | Alpha    | Beta  | Cap(B) |
|------------|--------|--------|----------|-------|--------|
| 2015-2017  | 5.0%   | 58.2%  | -24.0%   | -0.0  | 134.1  |
| 2016-2018  | 43.0%  | 66.4%  | 25.0%    | -0.1  | 182.1  |
| 2017-2019  | 40.0%  | 66.4%  | 11.0%    | 0.3   | 216.8  |
| 2018-2020  | 20.0%  | 66.4%  | 0.0%     | 0.3   | 195.0  |
| 2019-2021  | -1.0%  | 65.6%  | -50.0%   | 0.3   | 191.4  |
| 2020-2022  | 13.0%  | 69.5%  | 11.0%    | 0.3   | 277.1  |
| 2021-2023  | 31.0%  | 69.5%  | 13.0%    | 0.3   | 272.3  |
| 2022-2024  | -7.0%  | 69.5%  | -33.0%   | 0.2   | 248.5  |
| 2023-2025  | -60.0%  | 61.4%  | -113.0%  | 0.4   | 210.4  |

**Analysis:**

*   **CAGR (Compound Annual Growth Rate):** Fluctuates significantly, with recent periods showing negative growth.  The most recent period (-60.0%) is a major concern.
*   **MDD (Maximum Drawdown):**  High MDD values across all periods indicate significant volatility and potential risk.
*   **Alpha:**  Alpha is inconsistent, indicating MRK's performance relative to its benchmark varies widely.  The recent negative alpha (-113.0%) highlights significant underperformance.
*   **Beta:** Beta values are generally low, suggesting MRK's price is not strongly correlated with the overall market.
*   **Cap(B):** Market Cap has fluctuated, reflecting company performance. The recent Market Cap of 210.4 Billion suggests a large and established company.

### 2. Recent Stock Price Fluctuations

*   **Current Price:** 84.22
*   **Previous Close:** 84.21
*   **Change:** 0.01 (negligible change)
*   **5-day Moving Average:** 82.84
*   **20-day Moving Average:** 81.782
*   **60-day Moving Average:** 80.584

**Analysis:** The stock price shows a very slight increase from the previous close. The fact that the current price is above the 5, 20, and 60-day moving averages suggests a potential short-term upward trend.

### 3. Market Risk Indicators and Expected Return

*   **MRI (Market Risk Indicator):** 0.3285 (Low Risk)
*   **RSI (Relative Strength Index):** 55.43 (Neutral)
*   **PPO (Percentage Price Oscillator):** 0.4485 (Neutral)
*   **Hybrid Signal:** cash_0%_Buy 90% of cash (8 shares - Safe - MRI:0.33)
*   **Recent (20-day) Relative Divergence Change:** -0.6 (Short-term Decline)
*   **Expected Return:** 223.1% (Long-term, relative to S&P 500)

**Analysis:** The MRI indicates a low-risk environment. The RSI and PPO values are neutral. The hybrid signal suggests a strong buy recommendation. However, the recent decline in relative divergence is a negative signal. The high expected return is very optimistic and should be viewed with caution, as it's a long-term projection. The near-zero price change, though small, could indicate a period of consolidation or uncertainty following the news/events in section 4.

### 4. Recent News & Significant Events

*   **[2025-08-17]:** Major business developments, regulatory changes, or market events.
*   **[2025-08-16]:** Analysts discussing performance and outlook.
*   **[2025-08-19]:** Notable stock volatility.
*   **[2025-08-18]:** Market experts highlight risks and opportunities, advising monitoring.

**Analysis:** Recent news suggests that Merck is experiencing significant events that are causing volatility and attracting analyst attention. Investors should closely monitor news and company announcements.

### 5. Recent Earnings Analysis

| Date       | EPS  | Revenue     |
|------------|------|-------------|
| 2025-08-05 | 1.76 | 15.81 B$    |
| 2025-05-02 | 2.01 | 15.53 B$    |
| 2024-11-06 | 1.25 | 16.66 B$    |
| 2024-08-05 | 2.15 | 16.11 B$    |
| 2025-08-05 | 2.15 | 16.11 B$    |

**Analysis:**
EPS (Earnings Per Share) is volatile, with a recent decrease. Revenue has also fluctuated. This inconsistency in earnings could be contributing to the underperformance against the S&P 500.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter    | Revenue  | Profit Margin |
|------------|----------|---------------|
| 2025-06-30 | $15.81B  | 77.50%        |
| 2025-03-31 | $15.53B  | 77.98%        |
| 2024-12-31 | $15.62B  | 75.50%        |
| 2024-09-30 | $16.66B  | 75.51%        |
| 2024-06-30 | $16.11B  | 76.76%        |

**Capital and Profitability:**

| Quarter    | Equity   | ROE    |
|------------|----------|--------|
| 2025-06-30 | $48.99B  | 9.04%  |
| 2025-03-31 | $48.34B  | 10.51% |
| 2024-12-31 | $46.31B  | 8.08%  |
| 2024-09-30 | $44.50B  | 7.09%  |
| 2024-06-30 | $43.58B  | 12.52% |

**Analysis:**

*   **Revenue:** Relatively stable, with some fluctuation.
*   **Profit Margin:** Consistently high, indicating strong profitability.
*   **Equity:** Gradually increasing, suggesting growth and financial stability.
*   **ROE (Return on Equity):** Volatile, reflecting fluctuations in profitability relative to equity.

### 7. Overall Assessment

Merck & Co. Inc (MRK) is currently showing mixed signals. While the company maintains high-profit margins and a low MRI (market risk indicator), it has significantly underperformed the S&P 500. Recent earnings data shows inconsistency. Recent news and the near-zero price change suggest market uncertainty. The extremely high expected return is optimistic, but the company needs to address its recent underperformance and demonstrate consistent growth to justify that level of expectation. The current hybrid signal is a strong buy recommendation, suggesting that despite the negative performance, it is the right time to invest.
